Johnson & Johnson (JNJ) and Merck (MRK) are cutting jobs in China as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs, Bloomberg’s Amber Tong reports. The cuts at J&J have mainly impacted a division that sells products used in surgery, while Merck has scaled back its diabetes unit, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Johnson & Johnson announces results from ICONIC-LEADa Phase 3 study
- Eli Lilly sues to change hospital drug discount payments, WSJ reports
- Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts
- Wolfe starts J&J at Outperform, sees growth drivers as ‘best-in-class’